Internal Medicine, Hematology & Oncology · Hinsdale, IL
NPI
1831345818
Since 2008
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
4
Hospital affiliations
1 Salt Creek Ln
Hinsdale, IL, 60521
Phone (630) 286-5500
Groups this clinician bills Medicare through
Medicare paid, 2024
$64K
1,166 services
Medicare patients, 2024
368
Average age 75
Drug cost, 2024
$1.9M
1,003 prescriptions
Company payments, 2025
$421
From 12 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Arti Lakhani was code 99214 (office e&m - established), 377 times for 160 patients. In total Arti Lakhani billed 1,166 services in 20 codes, and Medicare paid $64K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2016-11-25.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 377 | 160 | $71.04 | $27K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 317 | 179 | $13.18 | $4,179 |
| 99213 Office E&M - Established | Office | 187 | 137 | $41.91 | $7,837 |
| 99215 Office E&M - Established | Office | 84 | 60 | $109.23 | $9,175 |
| 99232 Hospital E&M - Subsequent | Facility | 65 | 49 | $63.95 | $4,157 |
| 99222 Hospital E&M - Initial | Facility | 58 | 53 | $104.01 | $6,032 |
| 99233 Hospital E&M - Subsequent | Facility | 23 | 17 | $96.15 | $2,212 |
| 99221 Hospital E&M - Initial | Facility | 13 | 13 | $62.80 | $816 |
By year: 2022 $56K for 729 services; 2023 $90K for 1,153 services; 2024 $64K for 1,166 services.
Medicare prescription drug claims, 2024
In 2024, the drug Arti Lakhani prescribed most often to Medicare patients was Eliquis (Apixaban), with 165 prescriptions and refills. In total Arti Lakhani wrote 1,003 Medicare prescriptions that cost $1.9M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Eliquis Apixaban | 165 | 222 | 31 | $126K |
| Anastrozole Generic | 110 | 285 | 38 | $1,889 |
| Xarelto Rivaroxaban | 82 | 124 | 15 | $69K |
| Acyclovir Generic | 71 | 99 | 15 | $801 |
| Hydroxyurea Generic | 63 | 115 | 14 | $1,273 |
| Letrozole Generic | 40 | 83 | 12 | $642 |
| Tamoxifen Citrate Generic | 39 | 114 | 15 | $1,507 |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | 32 | 32 | Under 11 | $102 |
| Prochlorperazine Maleate Generic | 29 | 30 | 17 | $328 |
| Dexamethasone Generic | 18 | 28 | Under 11 | $222 |
| Exemestane Generic | 17 | 41 | Under 11 | $8,822 |
| Kisqali Ribociclib Succinate | 16 | 16 | Under 11 | $197K |
| Ondansetron Hcl Generic | 15 | 15 | 14 | $167 |
| Ibrance Palbociclib | 14 | 14 | Under 11 | $219K |
| Brukinsa Zanubrutinib | 14 | 14 | Under 11 | $206K |
Brand drugs: 393 claims; generic drugs: 610 claims; opioid claims: 14.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Arti Lakhani $421 ($421 in general payments such as food, travel and fees) from 12 companies. The largest payer was Genentech USA, Inc. with $89.13.
| Company | Payments | Amount |
|---|---|---|
| Genentech USA, Inc. ROG.SW | 4 | $89.13 |
| AstraZeneca Pharmaceuticals LP AZN | 2 | $53.36 |
| Incyte Corporation INCY | 2 | $47.13 |
| Novartis Pharmaceuticals Corporation NVS | 2 | $44.66 |
| Abbvie Inc. ABBV | 2 | $38.27 |
| Geron Corporation GERN | 1 | $26.22 |
| BeOne Medicines USA, Inc. ONC | 1 | $24.27 |
| Gilead Sciences, Inc. GILD | 1 | $20.77 |
| Merck Sharp & Dohme LLC MRK | 1 | $20.53 |
| Aveo Pharmaceuticals, Inc. | 1 | $20 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.